**Reimbursement Review**

**Reimbursement Status for Comparators**

**Instructions for Sponsors**

In this template, the sponsor is required to provide the publicly available listing status and criteria for all relevant comparators. Canada’s Drug Agency (CDA-AMC) may share this form with the federal, provincial, territorial governments, including their agencies and departments, the pan-Canadian Pharmaceutical Alliance (pCPA), and Canadian Blood Services.

Please read the instructions below and consult the recommended documentation before completing the template. If you have any questions regarding the CDA-AMC submission filing process or requirements, please [contact us](https://www.cda-amc.ca/contact-us) with the complete details of your question(s).

Before Completing the Template:

Please review the following documents to ensure an understanding of CDA-AMC’s procedures and submission guidelines:

* + [Procedures for Reimbursement Reviews](https://cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Drug_Reimbursement_Review_Procedures.pdf)
  + [Pharmaceutical Review Updates](https://www.cadth.ca/node/68411?keywords=&result_type%5B%5D=report&product_type%5B%5D=107782&sort=field_date%3Avalue-desc&amount_per_page=10&page=1) for any applicable information.

Completing the Template:

Complete the table based only on publicly available information. **Do not contact the individual drug programs or CDA-AMC for information on the reimbursement status of comparators**.

Please complete the appropriate section of the template:

* + Complete section 1 for non-oncology drugs (including plasma protein products)
  + Complete section 2 for oncology drugs

For oncology drugs that are administered intravenously (IV), please include information for British Columbia, Alberta, Saskatchewan, Ontario, and Prince Edward Island (other jurisdictions may not have this information publicly available). For oncology drugs that administered orally, please include all provincial drug programs.

Complete the reimbursement status for comparators tables as follows:

* + Add the non-proprietary and brand names for each relevant comparator
  + Use a separate row for each comparator
  + Use separate tables for each indication being reviewed by CDA-AMC
  + Use the following abbreviations to complete the table:

|  |  |
| --- | --- |
| **Abbreviation** | **Description** |
| **CDA-AMC** | Under review by CDA-AMC |
| **NEG** | Under review and/or negotiation by pan-Canadian Pharmaceutical Alliance or Canadian Blood Services |
| **EX** | Exception item for which coverage is determined on a case-by-case basis |
| **FB** | Full benefit |
| **FPT** | Under consideration by the federal, provincial, and territorial drug plans |
| **NB** | Not a benefit |
| **RES** | Restricted benefit with specified criteria (e.g., special authorization, exception drug status, limited use benefit) |
| **‒** | Information not available |

Complete the reimbursement criteria tables as follows:

* + For all restricted benefit entries (RES), please complete a separate reimbursement criteria table for each comparator.
  + For each entry, state the criteria used by each drug program.
  + Use a separate table for each indication and add or delete rows, as necessary.

When the template is complete, delete this cover page with the instructions (including the CDA-AMC document header) and the section of the template that is not applicable for the drug under review (i.e., section 1 or 2 as appropriate). Please feel free to add company-specific elements such as a disclaimer, header, footer, etc. as required. Save the completed template in PDF or Microsoft Word format

Filing the Completed Template:

Save the completed template as a Microsoft Word document and incorporate into the application package. Please consult the relevant procedural documentation for details on how to file the application with CDA-AMC.

CDA-AMC may update the information provided by the applicant with new information provided by the participating drug programs, as required.

**Reimbursement Review**

**Reimbursement Status for Comparators**

1. Submissions for Non-Oncology Drugs (including plasma protein products)

Reimbursement Status for Comparators for the Treatment of [State the Indication]

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Comparators | FPT Public drug programs | | | | | | | | | | | | | | | CBS |
| BC | AB | SK | MN | ON | NB | NS | PE | NL | YT | NT | NIHB | CAF | VAC | CSC |
| **Brand (generic)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Brand (generic)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

AB = Alberta; BC = British Columbia; CDA-AMC = under review by CDA-AMC; CBS = Canadian Blood Services; CSC = Correctional Services Canada; CAF = Canadian Armed Forces; EX = exception item for which coverage is determined on a case-by-case basis; FB = full benefit; MN = Manitoba; FPT= Under consideration by the federal, provincial, and territorial drug plans; NIHB = Non-Insured Health Benefits Program; NL = Newfoundland and Labrador; NB = not a benefit; NEG = Under review and/or negotiation by pan-Canadian Pharmaceutical Alliance or Canadian Blood Services; NS = Nova Scotia; NT = Northwest Territories; ON = Ontario; PE = Prince Edward Island; RES = restricted benefit with specified criteria; SK = Saskatchewan; VAC = Veterans Affairs Canada; YT = Yukon; ‒ = Information not available

2. Submissions for Oncology Drugs

Reimbursement Status for Comparators for the Treatment of [State the Indication]

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Comparators | Public drug programs | | | | | | | | | |
| BC | AB | SK | MN | ON | NB | NS | PE | NL | NIHB |
| **Brand (generic)** |  |  |  |  |  |  |  |  |  |  |
| **Brand (generic)** |  |  |  |  |  |  |  |  |  |  |

AB = Alberta; BC = British Columbia; CDA-AMC = under review by CDA-AMC; EX = exception item for which coverage is determined on a case-by-case basis; FB = full benefit; MN = Manitoba; FPT= Under consideration by the federal, provincial, and territorial drug plans; NIHB = Non-Insured Health Benefits Program; NL = Newfoundland and Labrador; NB = not a benefit; NEG = Under review and/or negotiation by pan-Canadian Pharmaceutical Alliance; NS = Nova Scotia; ON = Ontario; pCPA = under negotiation by the pan-Canadian Pharmaceutical Alliance; PE = Prince Edward Island; RES = restricted benefit with specified criteria; SK = Saskatchewan; ‒ = Information not available

Reimbursement Criteria for (Comparator) for (State the Indication)

|  |  |
| --- | --- |
| Drug plan | Criteria for restricted benefit |
| Add name | State the exact criteria (if publicly available) |
| Add name | State the exact criteria (if publicly available) |